4523.T
Stock Details
4523.T is Eisai Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 5,463.42๏ฟฅ. Average daily volumn in 3 months 961.1k. Market cap 1.64T
Stock symbol : 4523.T. Exchange : Tokyo. Currency : JPY Lastest price : 5,712.00๏ฟฅ. Total volume : 813.00k. Market state PREPRE Click reload if you want to check the lastest price on market!!!
Eisai Co., Ltd. (4523.T)
Last Price
5,712.00๏ฟฅChange
92.00Volume
813.00k
| Previous Close | 5,620.00 |
| Open | 5,616.00 |
| Day Range | 5,578.00-5,715.00 |
| Bid | 5,708.00 x N/A |
| Ask | 5,715.00 x N/A |
| Volume | 813k |
| Average Volume | 961.1k |
| Market Cap | 1.64T |
| Beta | 0.47 |
| 52 Week Range | 5,011.00-11,640.00 |
| Trailing P/E | 34.15 |
| Foward P/E | 32.15 |
| Dividend (Yield %) | 3.13% |
| Ex-Dividend Date | 2022-09-29 |
Financial Details
Organization
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted... medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Market Cap:
1.64TRevenue:
756.23BTotal Assets:
1.24TTotal Cash:
309.63B
News about "Eisai Co., Ltd."
E.Design Insurance and Eisai Enter Into Business Alliance
Source from : The Globe and Mail - 11 hours ago
TOKYO, Jun 28, 2022 - (JCN Newswire) - E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have ...See details»
Eisai (OTCMKTS:ESALY) Sets New 12-Month Low at $36.88
Source from : Defense World - 11 days ago
Eisai Co., Ltd. (OTCMKTS:ESALY โ Get Rating) shares hit a new 52-week low during trading on Friday . The company traded as low as $36.88 and last traded at $37.90, with a volume of 37780 shares ...See details»
Eisai Co. Ltd. ADR
Source from : Wall Street Journal - 11 days ago
Yoshiteru Kato Director Eisai Co., Ltd., Eisai Manufacturing Ltd. Hideki Hayashi Director Eisai Co., Ltd., Ea Pharma Co., Ltd. Yutaka Tsuchiya Director Eisai Co., Ltd ...See details»
Eisai Co., Ltd. (4523)
Source from : Investing - 13 days ago
At the close in... Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimerโs disease/dementia with Lewy bodies; Methycobal for the treatment of ...See details»
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
Source from : Asia One - 4 days ago
Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of ...See details»
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
Source from : Asia One - 6 days ago
Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril ...See details»
Eisai Co Ltd - Stock Dividends ESALF
Source from : Morningstar%2c Inc. - 13 days ago
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING
Source from : Yahoo Finance - 26 days ago
NUTLEY, N.J., June 2, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today a total of seven poster presentations including the latest data on its ...See details»
Eisaiโs brain health tool NouKNOW used in Tokyo dementia project
Source from : pharmaphorum - 5 days ago
Eisaiโs digital tool to allow self-assessment of cognitive performance โ NouKNOW โ will be used in a Japanese project aimed at improving the management of dementia. The smartphone app โ which uses a ...See details»
New Strong Sell Stocks for June 8th
Source from : Nasdaq - 20 days ago
Eisai Co., Ltd. ESALY is a pharmaceutical company from Japan. The Zacks Consensus Estimate for its current year earnings has been revised 17.5% downward over the last 60 days. View the entire ...See details»
Japanโs five hottest biotech companies in healthcare
Source from : the Top 10 - 13 days ago
While historically lacking in foreign investments, Japanโs biotech scene is now thriving with global investors showing increasing interest. Here are five of the hottest Japanese private companies ...See details»
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
Source from : Business Insider - 23 days ago
co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). The safety and efficacy findings are being featured in a poster discussion at the 2022 American Society of ...See details»
Protein Tyrosine Kinase Market Size, Share, Price Trend by Type, Segment Analysis by Application and Regional Forecast-2028
Source from : MarketWatch - 8 days ago
The Protein Tyrosine Kinase Market (2022-2028) Research report investigates the effect of the pandemic on the Protein Tyrosine Kinase market from a Global and Regional viewpoint. The report frames the ...See details»
Insomnia Market Prognosticated For A Ravishing Growth By 2030 | Minerva Neurosciences Inc, Currax Pharmaceuticals LLC, Eisai
Source from : Digital Journal - 14 days ago
New Jersey, United StatesโInsomnia is a typical rest problem that can make it hard to nod off, difficult to stay unconscious or cause to get up too soon and not have the option to return to rest.See details»